Literature DB >> 24108603

Utility of specimens positive for Neisseria gonorrhoeae by the Aptima Combo 2 assay for assessment of strain diversity and antibiotic resistance.

Kanti Pabbaraju1, Sallene Wong, Joanna J Song, Ameeta E Singh, Ron Read, Steven J Drews.   

Abstract

In our jurisdiction, the Aptima Combo 2 assay (Gen-Probe, Inc.) is used to detect Neisseria gonorrhoeae from specimens collected at clinics for sexually transmitted infections (STI) and from select community patients. In addition, swabs are also collected for N. gonorrhoeae culture, susceptibility testing, and sequence typing (ST). Since only a small proportion of samples from provincial cases undergo culture, the available trends in antimicrobial susceptibility and predominant strain types may not be representative of all N. gonorrhoeae infections. Due to the limitations facing the use of N. gonorrhoeae culture to understand these trends in the general community, we performed a molecular analysis for markers of cephalosporin resistance and ST determination by using nucleic acid extracts of specimens sent for Aptima testing. Thirty-four samples submitted for both Aptima testing and N. gonorrhoeae culture from the same anatomic location (within 24 h) were included in the study. Sequence type was determined based on the sequence of the por and tbpB genes, and amino acid changes in the PBP 2 protein, encoded by the penA gene, were considered representative for the assessment of antimicrobial susceptibility. Sequence identity of 100% was observed between the sequences obtained from Aptima-analyzed samples and culture samples. Sequencing results showed an association between decreased susceptibility to extended-spectrum cephalosporins (ESC(ds)), tbp allele 110, ST 1407, and amino acid changes (G545S, I312M, and V316T) in the PBP 2 protein. Our data, generated based on a few representative genes, suggest that gonococcal samples positive by Aptima testing can be used to determine single nucleotide polymorphisms associated with ESC(ds) and the sequence type based on molecular strain typing. Confirmation of these findings may obviate the need for gonorrhea culture in the future.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24108603      PMCID: PMC3838053          DOI: 10.1128/JCM.01694-13

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  24 in total

1.  Trends in antimicrobial resistance in Neisseria gonorrhoeae isolated in Canada: 2000-2009.

Authors:  Irene Martin; Gayatri Jayaraman; Tom Wong; Gary Liu; Matthew Gilmour
Journal:  Sex Transm Dis       Date:  2011-10       Impact factor: 2.830

Review 2.  The Gonococcus fights back: is this time a knock out?

Authors:  David A Lewis
Journal:  Sex Transm Infect       Date:  2010-07-23       Impact factor: 3.519

3.  Molecular epidemiological typing within the European Gonococcal Antimicrobial Resistance Surveillance Programme reveals predominance of a multidrug-resistant clone.

Authors:  S A Chisholm; M Unemo; N Quaye; E Johansson; M J Cole; C A Ison; M J Van de Laar
Journal:  Euro Surveill       Date:  2013-01-17

4.  Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone.

Authors:  Makoto Ohnishi; Daniel Golparian; Ken Shimuta; Takeshi Saika; Shinji Hoshina; Kazuhiro Iwasaku; Shu-ichi Nakayama; Jo Kitawaki; Magnus Unemo
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

5.  Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada.

Authors:  Vanessa G Allen; Leo Mitterni; Christine Seah; Anuradha Rebbapragada; Irene E Martin; Colin Lee; Heather Siebert; Lynn Towns; Roberto G Melano; Donald E Low
Journal:  JAMA       Date:  2013-01-09       Impact factor: 56.272

6.  Gonococcal resistance: are cephalosporins next?

Authors:  Robert D Kirkcaldy; Ronald C Ballard; Deborah Dowell
Journal:  Curr Infect Dis Rep       Date:  2011-04       Impact factor: 3.725

7.  High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure.

Authors:  Magnus Unemo; Daniel Golparian; Robert Nicholas; Makoto Ohnishi; Anne Gallay; Patrice Sednaoui
Journal:  Antimicrob Agents Chemother       Date:  2011-12-12       Impact factor: 5.191

8.  Genome sequencing of a Neisseria gonorrhoeae isolate of a successful international clone with decreased susceptibility and resistance to extended-spectrum cephalosporins.

Authors:  David Hess; Abel Wu; Daniel Golparian; Sarah Esmaili; Will Pandori; Emilee Sena; Jeffrey D Klausner; Pennan Barry; Magnus Unemo; Mark Pandori
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

Review 9.  The use of cephalosporins for gonorrhea: the impending problem of resistance.

Authors:  Pennan M Barry; Jeffrey D Klausner
Journal:  Expert Opin Pharmacother       Date:  2009-03       Impact factor: 3.889

10.  Molecular characterization of two high-level ceftriaxone-resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain.

Authors:  Jordi Cámara; Judit Serra; Josefina Ayats; Teresa Bastida; Dolors Carnicer-Pont; Antònia Andreu; Carmen Ardanuy
Journal:  J Antimicrob Chemother       Date:  2012-05-07       Impact factor: 5.790

View more
  2 in total

1.  Molecular Assay for Detection of Genetic Markers Associated with Decreased Susceptibility to Cephalosporins in Neisseria gonorrhoeae.

Authors:  S W Peterson; I Martin; W Demczuk; A Bharat; L Hoang; J Wylie; V Allen; B Lefebvre; G Tyrrell; G Horsman; D Haldane; R Garceau; T Wong; M R Mulvey
Journal:  J Clin Microbiol       Date:  2015-04-15       Impact factor: 5.948

2.  Chlamydia trachomatis genotypes in a cross-sectional study of urogenital samples from remote Northern and Central Australia.

Authors:  Philip M Giffard; Nicole C Brenner; Sepehr N Tabrizi; Suzanne M Garland; Deborah C Holt; Patiyan Andersson; Rachael A Lilliebridge; Steven Y C Tong; Mahdad Karimi; Prudence Boylan; Nathan Ryder; Tracy Johns; Gurmeet Singh
Journal:  BMJ Open       Date:  2016-01-06       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.